Sign In
Last checked at 
10 Feb 2021 17:00
10 February 2021
Kainos Group plc
("Kainos" or the "Company")
Director/PDMR Shareholdings
The Company was notified on 9 February 2021, that Paul Gannon, Director, sold 200,000 ordinary shares in the Company at an aggregated price of £13.35 per ordinary share.
The Company was further notified on 10 February 2021, that Mr Gannon transferred 50,000 ordinary shares in the Company to a Family Partnership for nil consideration.
Following this notification, Paul Gannon and his Connected Persons have a reportable shareholding of 7,729,008 ordinary shares in the issued share capital of the Company constituting 6.3% of the issued share capital of the Company.
Director / PDMR shareholdings
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a. | Name | Paul Gannon | ||||
2. | Reason for the notification | |||||
a. | Position/status | Director | ||||
b. | Initial notification /Amendment | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a. | Name | Kainos Group plc | ||||
b. | LEI | 213800H2PQMIF3OVZY47 | ||||
4.(i) | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument/ type of instrument Identification code | Ordinary Shares of £0.005 each
KNOS | ||||
b. | Nature of the transaction | Sale of Shares | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information · Aggregated volume · Price |
N/A | ||||
e. | Date of the transaction | 09- February | ||||
f. | Place of the transaction | LSE - Regulated Market - XLON | ||||
4.(ii) | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument/ type of instrument Identification code | Ordinary Shares of £0.005 each
KNOS | ||||
b. | Nature of the transaction | Transfer of shares into a Family Partnership | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information · Aggregated volume · Price |
N/A | ||||
e. | Date of the transaction | 10-February-2020 | ||||
f. | Place of the transaction | LSE - Regulated Market - XLON | ||||
Kainos Group plc Legal Entity Identifier: 213800H2PQMIF3OVZY47
Ends
For further information, please contact:
Kainos via FTI Consulting LLP
Brendan Mooney, Chief Executive Officer
Richard McCann, Chief Financial Officer
Investec Bank plc +44 20 7597 5970
Patrick Robb / Ben Griffiths
Canaccord Genuity +44 20 7523 4606
Simon Bridges/ Emma Gabriel
FTI Consulting LLP +44 20 3727 1000
Matt Dixon / Dwight Burden / Kwaku Aning
About Kainos
Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms.
The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. ('Workday'), responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers.
The Group's Digital Platforms comprise specialised digital platforms in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.
Kainos has over 1,700 people across 15 offices in Europe and North America.
Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com.
Follow the stocks
